In 2015-2016, Kevin Krenitsky served as President of OpGen (NASDAQ:OPGN) and oversaw the rollout of the company’s Acuitas® MDRO family of Gene Tests and the development of Acuitas Lighthouse™ MDRO Management System. Dr. Krenitsky has more than 15 years of experience leading and managing global diagnostic and biotechnology operations, including as Chief Commercial Officer & SVP of International Strategy and previously Chief Operating Officer of Foundation Medicine (NASDAQ: FMI). Prior to Foundation Medicine, he served as President of Enzo Clinical Labs, a wholly owned subsidiary of Enzo Biochem (NYSE:ENZ), where he instituted a comprehensive strategic and operational plan that led to the launch of numerous FDA-approved esoteric tests, as well as several new laboratory developed tests. Dr. Krenitsky served as Chief Executive Officer at both BioServe Biotechnologies, a global biotechnology company specializing in processing genetic diagnostic tests, and Parkway Clinical Laboratories, a clinical diagnostic lab providing comprehensive routine and esoteric testing. He also held various senior-level positions within Genomics Collaborative, Inc. (a SeraCare Life Sciences Company), a full-scale clinical and genomics research company, and is a former Board member of the New York State Clinical Lab Association.

Dr Howard McLeod is an internationally recognized expert in precision medicine, having made novel contributions at the discovery, translation, implementation, and policy levels. He is the Medical Director for Precision Medicine at the Geriatric Oncology Consortium and a Professor at the University of South Florida Taneja College of Pharmacy. He was previously the Medical Director of the DeBartolo Family Personalized Medicine Institute at the Moffitt Cancer Center. He also chaired the Department of Individualized Cancer Management, was a Senior Member in the Department of Cancer Epidemiology, and a State of Florida Endowed Chair in Cancer Research. Dr McLeod chaired the NHGRI eMERGE network external scientific panel for the past decade and was a recent member of both the FDA committee on Clinical Pharmacology and the NIH Human Genome Advisory Council. Dr McLeod has been recognized as a Fellow of the American Society of Clinical Oncology and the American College of Clinical Pharmacy and was recently ranked #1 USA/#2 World for Pharmacogenomics. He has also been an active Board Member and/or Founder for over a dozen privately held and publicly traded companies. Howard has published over 575 peer reviewed papers on pharmacogenomics, applied therapeutics, or clinical pharmacology and continues to work to advance innovative healthcare.

Dr. Murphy is the Managing Partner of his successful medical practice, where he took the lead on COVID19 testing in the United States. Developing a multimillion dollar scalable laboratory and being the first to bring drive thru testing to the East Coast, Dr. Murphy has deep experience in clinical and laboratory operations as well as revenue cycle management. Dr. Murphy serves as an Assistant Professor in the Department of Anatomy and Cell Biology at New York Medical College where he teaches and create curricula in genetics for the Pathology and Biochemistry courses. A board certified physician with training in Clinical Genetics and Internal Medicine from the Yale School of Medicine Dr. Murphy is familiar with the esoteric tests required to transform medicine to a precision based profession and the financial management needed to operate in the current and future regulatory environment.

Kris brings more than 25 years of experience as a Senior Transformational Program Leader in global Pharmaceutical, Financial Services and Technology Startups environments. Companies included Novartis, Regeneron, Pfizer, Express Scripts, Medco, World Bank, Freddie Mac, Fannie Mae, Merrill Lynch, Oppenheimer Funds, Dun & Bradstreet and IBM. CEO Co-founder of startups; New Century Systems, Nitorum Corporation, Reconda International Corporation, Hypertomic Inc and Total Dx Connect Inc. Currently consulting at Novartis in Patient Specialty Services (PSS) Portals for brands Xiidra, Cosentyx, ILaris and Transplant managing Portal, Hub, CoPay, Adherence, ePA and Map. Previous Novartis assignment; managed Global migration and deployment of GxP SaaS Drug Development NVS Connect Portal to 180,000 users in 120 countries; 2,500 studies; 35,000 Safety Notifications. Extensive experience with application & data integration / migrations, portals, ETL, SaaS, data warehousing, risk and compliance, finance / budgets, change management, data governance, business process re-engineering, workflow & modeling, performance / metrics, CMS, Vendor – business requirements / RFP / selection / contracts / management.

Successful Sales and Marketing executive for Specialty Chemicals, Pharmaceutical Intermediates & Nutritional Ingredients industries. Organized, positioned, and managed successful several startup companies in the Pharma and Nutritional space. Established Sales & Marketing for Optigenex, Inc. Targeted and closed companies including Bayer, Wyeth, Herbalife, Merck, Clinique’s, Protein R&D. Organized and executed strategic meetings with the CEO, President and Sr Scientific Officer of MEDCO for the partnership with Guide Diagnostics Corporation platform provides Integration, Interpretation and Guidance of Genetic Testing). Formed Hill Pharma Inc. creating the Brand, Development, website. Identified customer targets and closed on $50mm in business within 42 months. Kelly’s Sales, Marketing and Science background allowed his expertise to meet with prospective client opportunities and close on such business.

As Vice President leading SVB’s Northeast Life Science Startup Banking Practice, Kaitlin Berube brings her passion for early-stage development to founders in the businesses of biopharma, diagnostics, medical devices, health-tech and medical services. Among her many skills: connecting entrepreneurs with potential investors and talented new hires that position their startups to thrive.

John serves as the firmwide chair of Baker Hostetler’s Business Group and is a member of the firm’s Policy Committee. He is also a member of the Cleveland office’s Hiring Committee. John is ranked in Chambers USA: America’s Leading Lawyers for Business in Ohio Corporate / M&A.